Experimental studies with liarozole (R 75,251): an antitumoral agent which inhibits retinoic acid breakdown.
Liarozole reduced tumor growth in the androgen-dependent Dunning-G and the androgen-independent Dunning MatLu rat prostate carcinoma models as well as in patients with metastatic prostate cancer who had relapsed after orchiectomy. In vitro, liarozole did not have cytostatic properties, as measured by cell proliferation in breast MCF-7 and prostate DU145 and LNCaP carcinoma cell lines. It did not alter the metabolism of labeled testosterone i.e. the 5 alpha-reductase in cultured rat prostatic cells. In mouse F9 teratocarcinoma cells liarozole did not show any retinoid-like properties but enhanced the plasminogen activator production induced by retinoic acid. Furthermore, liarozole and retinoic acid similarly reduced the growth of the androgen-dependent Dunning-G tumor in nude mice and inhibited tumor promotion elicited by phorbol ester in mouse skin. These data have raised the hypothesis that the antitumoral properties of liarozole may be related to inhibition of retinoic acid degradation, catalyzed by a P-450-dependent enzyme that is blocked by the drug.
De Coster
R
R
Janssen Research Foundation, Beerse, Belgium.
Wouters
W
W
Van Ginckel
R
R
End
D
D
Krekels
M
M
Coene
M C
MC
Bowden
C
C
D000818:Animals; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002455:Cell Division / Q000187:drug effects; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D009374:Neoplasms, Experimental / Q000188:drug therapy / Q000378:metabolism; D010960:Plasminogen Activators / Q000378:metabolism; D013739:Testosterone / Q000378:metabolism; D013755:Tetradecanoylphorbol Acetate / Q000494:pharmacology; D014212:Tretinoin / Q000378:metabolism*
D000970:Antineoplastic Agents; D007093:Imidazoles; D013739:Testosterone; D014212:Tretinoin; D010960:Plasminogen Activators; C061121:liarozole; D013755:Tetradecanoylphorbol Acetate